摘要
目的探讨核苷酸切除修复交叉互补组基因1(ERCC1)和人类X射线交错互补修复基因1(XRCC1)单核苷酸多态性(SNP)与接受以奥沙利铂为基础的化疗方案治疗晚期结直肠癌(CRC)疗效的关系。方法选取2017年11月至2019年4月收治于荆门市第一人民医院经病理组织学确诊为晚期直肠癌病人95例,均接受含奥沙利铂为基础的化疗方案化疗至少3个周期后评价疗效。采用荧光染色原位杂交测序法对化疗病人外周血中ERCC1 Asn118Asn、XRCC1 Gln399Arg基因型进行检测,分析各基因型与CRC病人近期化疗疗效的相关性。结果本研究所选取的病人中各多态性位点的基因型分布均符合HardyWeinberg平衡。病人的性别、年龄、结直肠癌分期(TNM分期)、肿块部位(结肠部位、直肠部位)和含奥沙利铂为基础的化疗方案疗效均差异无统计学意义(P>0.05)。95例CRC病人中,携带ERCC1 Asn118Asn GG、AG+AA基因型的病人化疗后有效率分别为51.9%(28/54)和24.4%(10/41),ERCC1 Asn118Asn AG+AA基因型病人化疗失败的可能性是GG型的3.338倍,OR=3.338,95%CI为1.370~8.134,P<0.05;携带XRCC1 Gln399Arg CC、TC+TT基因型的病人化疗后有效率分别为52.0%(26/50)和26.7%(12/45),XRCC1 Gln399Arg TC+TT基因型病人化疗失败的可能性是CC型之间的2.979倍,OR=2.979,95%CI为1.257~7.060,P<0.05。结论就含奥沙利铂为基础联合化疗失败的可能性而言,携带ERCC1 Asn118Asn AG+AA基因型比GG型高;携带XRCC1 Gln399Arg TC+TT基因型比CC型高。检测ERCC1 Asn118Asn和XRCC1 Gln399Arg单核苷酸多态性可以成为预测结直肠癌病人接受含奥沙利铂为基础的化疗方案疗效的指标。
Objective To study the relationship between single nucleotide polymorphisms(SNP)in the ERCC1(excision repair cross complementation group 1),XRCC1(X-ray cross complementing repair gene 1)and clinical outcome of patients with advanced colorectal cancer treated with oxaliplatin-based chemotherapy.Methods A total of 95 patients pathologically diagnosed as advanced colorectal cancer by histopathology admitted to Jingmen NO.1 People’s Hospital from November 2017 to April 2019 were collected.After all patients received oxaliplatin-based chemotherapy for at least 3 cycles of chemotherapy,the efficacy had been evaluated,also he correlation between each genotype and the short-term efficacy of patients with advanced colorectal cancer had been analyzed.Results(1)The genotype distribution of each polymorphism was found to be of Hardy-Weinberg equilibrium in the study.There was no significant correlation among gender,age,colorectal cancer stage(TNM stage),tumor site with chemotherapy efficacy(P>0.05).(2)Among the 95 CRC patients,the effective rate of patients with ERCC1 Asn118 Asn GG and AG+AA genotypes after chemotherapy was 51.9%(28/54)and 24.4%(10/41),Patients with XRCC1 Gln399 Arg TC+TT genotype were 2.979 times more likely to fail chemotherapy than those with CC genotype.OR=3.338,95%CI:1.370-8.134,P<0.05;The effective rate of patients with XRCC1 Gln399 Arg CC,TC+TT genotypes after chemotherapy was 52.0%(26/50)and 26.7%(12/45),Patients with TC+TT genotype were 2.979 times more likely to fail chemotherapy than those with CC genotype.OR=2.979,95%CI:1.257-7.060,P<0.05.Conclusions In terms of the possibility of failure of oxaliplatin based chemotherapy,the genotype carrying ERCC1 asn118 asn Ag+AA was higher than that of GG genotype;the genotype carrying XRCC1 gln399 arg TC+TT was higher than CC genotype;detection of the single nucleotide polymorphisms of ERCC1 Asn118 Asn and XRCC1 Gln399 Arg may be used as a predictor of the efficacy of oxaliplatin-based chemotherapy in colorectal cancer patients.
作者
李林子
李昌海
谢雄伟
刘晨晖
杨娥
韦智丹
廖秋霞
LI Linzi;LI Changhai;XIE Xiongwei;LIU Chenhui;YANG E;WEI Zhidan;LIAO Qiuxia(Department of Pharmacy,Jingmen NO.1 People’s Hospital,Jingmen,Hubei 448000,China;Gastrointestinal Surgery,Jingmen NO.1 People’s Hospital,Jingmen,Hubei 448000,China)
出处
《安徽医药》
CAS
2021年第1期9-12,共4页
Anhui Medical and Pharmaceutical Journal
基金
荆门市科技计划项目(2018YFYB024)。
